Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: Immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104)

Clinical Cancer Research

Volumn 11, Issue 1, 2005, Pages 290-297

  Asemissen, Anne Marie ^a   Scheibenbogen, Carmen ^a   Letsch, Anne ^a   Hellstrand, Kristoffer ^b   Thorén, Fredrik ^b   Gehlsen, Kurt ^c   Schmittel, Alexander ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a,d  

^a Medizinische Klinik I   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Maxim Pharmaceuticals Inc   (United States)

^d Hematol Oncol and Transfus Med   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; HISTAMINE; HLA A2 ANTIGEN; INTERLEUKIN 13; INTERLEUKIN 2; IONOMYCIN; PHORBOL MYRISTATE;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER METASTASIS; MELANOMA; MULTICENTER STUDY; PERIPHERAL LYMPHOCYTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; UVEA MELANOMA;

ANTIGENS, CD3; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; FLOW CYTOMETRY; HISTAMINE; HISTOCOMPATIBILITY TESTING; HUMANS; INTERFERON TYPE II; INTERLEUKIN-13; INTERLEUKIN-2; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MONOCYTES; NEOPLASM METASTASIS; PEPTIDES; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 11344279986     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002;12:43-50.
2. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002;29:35-40.
3. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26:1308-13.
4. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996;156:42-7.
5. Hellstrand K, Hermodsson S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol 1991;34:741-52.
6. Hellstrand K, Mellqvist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997;27:429-38.
7. Hellstrand K, Naredi P, Lindner P, et al. Histamine in immunotherapy of advanced melanoma: a pilot study. Cancer Immunol Immunother 1994;39:416-9.
8. Schmidt H, Larsen S, Bastholt L, Fode K, Rytter C, Von Der Maase H. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma. Ann Oncol 2002;13:1919-24.
9. Agarwala SS, Hellstrand K, Gehlsen K, Naredi P. Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother 2004;53:840-1.
10. Agarwala SS, Glaspy J, O'Day SJ, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-33.
11. Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 2002;23:255-63.
12. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420-5.
13. Jutel M, Klunker S, Akdis M, et al. Histamine upregulates Th1 and downregulates Th2 responses due to different patterns of surface histamine 1 and 2 receptor expression. Int Arch Allergy Immunol 2001;124:190-2.
14. Osna N, Elliott K, Khan MM. The effects of histamine on interferon γ production are dependent on the stimulatory signals. Int Immunopharmacol 2001;1:135-45.
15. Poluektova LY, Khan MM. Protein kinase A inhibitors reverse histamine-mediated regulation of IL-5 secretion. Immunopharmacology 1998;39:9-19.
16. Osna N, Elliott K, Khan MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001;1:85-96.
17. Elliott KA, Osna NA, Scofield MA, Khan MM. Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells. Int Immunopharmacol 2001;1:1923-37.
18. Dohlsten M, Hedlund G, Sjögren HO, Carlsson R. Inhibitory effects of histamine on interleukin 2 and γ interferon production of different human T helper cell subsets. Scand J Immunol 1988;28:727-33.
19. Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 1999;19:1135-44.
20. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619-28.
21. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998;160:5869-73.
22. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
23. Scheibenbogen C, Schadendorf D, Bechrakis NE, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003;104:188-94.
24. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
25. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 2004;172:1380-90.
26. Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003;13:449-59.